New Cervical Cancer Screening Guidelines Highlight the Importance of Actionable Results
The ASCCP's recent 2012 Updated Consensus Guidelines for Management of Abnormal Cervical Cancer Screening Tests and Cancer Precursors underscore the impact of abnormal cytology, particularly unsatisfactory and ASCUS results.
Learn more about the importance of actionable results in this educational promotional supplement to Contemporary Ob/Gyn. Co-authored by Dorothy Rosenthal, MD of The Johns Hopkins Hospital and Douglas Malinowski, PhD of BD Diagnostics, this white paper reviews the impact of unsatisfactory LBC specimens on cervical cancer screening and details data that demonstrate that a single sample does not always provide sufficient specimen to conduct both Pap and HPV tests.
You can also find out more live at the 2013 American College of Obstetrics and Gynecology annual meeting in New Orleans, May 4-8.
Visit BD Diagnostics at Booth #304 and attend our product theater on Wednesday, May 8th, 12-1pm to learn more about
Practical Considerations with the New Cervical Cancer Screening Guidelines.
Topics will include:
• Clinical Implications of HPV Genotype Specific Information
Dr. Jennifer S. Smith, The University of North Carolina
• The Importance of Actionable Results
Dr. Armanda D. Tatsas, The Johns Hopkins Hospital
• The UK LBC Experience
Dr. Douglas P. Malinowski, BD Diagnostics
Study finds reduced CIN3+ risk from early HPV vaccination
April 16th 2024A recent study found that human papillomavirus vaccination when aged under 20 years, coupled with active surveillance for cervical intraepithelial neoplasia grade 2, significantly lowers the risk of cervical intraepithelial neoplasia grade 3 or cervical cancer.
Read More
